Entest BioMedical Announces Creation of Proprietary Adult Stem Cell Lines
09 March 2010 - 12:00AM
Marketwired
Entest BioMedical Inc. (OTCBB: ENTB) announced today the creation
of 3 bone marrow derived stem cell lines useful for optimizing
laser intensities and wavelengths in laser enhanced stem cell
therapy. A stem cell line is a defined cell population that is
derived from a single cell and has the capability to replicate for
long periods of time in vitro. Proprietary stem cell lines are
commonly licensed for various applications ranging from research to
product development.
The Company believes the development of these stem cell lines
will assist in the progress of its stem cell therapy for COPD
treatment.
These cells, ENT-CL101, ENT-CL221, and ENT-CL303, similar in
nature to mesenchymal stem cells, are stable in cell culture, and
can be expanded en masse for wide-scale screening.
"The creation of a standardized platform for assessing
light-based therapies in vitro allows for mass screening for
specific biological properties in the same way that drug companies
screen small molecules," said Dr. Feng Lin, Director of Research
and Development. "This is unique not only in the fact that we are
using lasers instead of drugs for screening, but also that the
targets are stem cell lines. The cell lines we have developed are
also potentially useful for Pharmaceutical companies to screen
agents that activate stem cells."
The traditional model of drug discovery involves screening
thousands to millions of compounds in vitro on cells that represent
the disease state. For example, if one is developing cancer
therapeutics, the cancer cells are treated with random compounds
and the compounds that kill the cells in vitro are chosen for
animal testing. The creation of ENT-CL101, ENT-CL221, and ENT-CL303
allows for the same approach to be used in the area of light
therapy. To date identification of appropriate frequencies and
intensities for therapy is based on direct testing in animals,
which is extremely costly.
The platform developed by Entest is anticipated to substantially
save the cost of therapeutics development in the area of
regenerative photoceuticals.
"We are extremely proud of the out of the box approach that our
scientists have developed, which basically takes the area of
laser-based therapy into the 21st Century drug development arena,"
said David Koos, Chairman and CEO of Entest.
About Entest BioMedical Inc.:
Entest BioMedical Inc. (OTCBB: ENTB) is involved with the
development of stem cell therapy treatments for Chronic Obstructive
Pulmonary Disease (COPD), immuno-cancer therapies, testing
procedures for diabetes, stem cell research applications for
diabetes and other illnesses. The Company also is involved with
medical device development (including stem cell extraction
instrumentation). ENT - 576™ is a proprietary laser device
currently under development by Entest. The Company has filed 3
patent applications relating to the treatment of COPD. Entest
Biomedical Inc. is a majority owned subsidiary of Bio-Matrix
Scientific Group Inc. (OTCBB: BMSN). Recently Entest published in
the peer reviewed literature its platform technology, which is
available at
http://www.translational-medicine.com/content/pdf/1479-5876-7-106.pdf.
About Bio-Matrix Scientific Group:
Bio-Matrix Scientific Group Inc. (OTCBB: BMSN) is a
biotechnology company headquartered in San Diego, Ca. with a 15,000
sq. ft. facility that houses two secure cryogenic stem cell banks,
three research laboratories, aseptic cellular/tissue class
10,000/100 processing lab, hematology, microbiology and flow
cytometry laboratories. David Koos serves as Chairman & CEO
concurrently for BMSN and ENTB.
Disclaimer
This news release may contain forward-looking statements.
Forward-looking statements are inherently subject to risks and
uncertainties, some of which cannot be predicted or quantified.
Future events and actual results could differ materially from those
set forth in, contemplated by, or underlying the forward-looking
statements. The risks and uncertainties to which forward-looking
statements are subject include, but are not limited to, the effect
of government regulation, competition and other material risks.
Contact: Entest BioMedical Inc. David R. Koos, Chairman &
CEO 619.702.1404 Direct 619.330.2328 Fax info@EntestBio.com
www.EntestBio.com Bio-Matrix Scientific Group Inc. www.BMSN.us
info@BMSN.us Follow the Company's progress on Twitter:
http://twitter.com/Entest_BioMed